PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1532778
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1532778
Tumor Transcriptomics Market size was valued at USD 5,790.10 Million in 2023, expanding at a CAGR of 10.10% from 2024 to 2032.
Tumor transcriptomics involves analyzing the gene expression profiles of tumors by examining RNA molecules (transcripts). This method identifies genes that are either over-expressed or under-expressed compared to healthy tissue, revealing the molecular characteristics of tumors. This approach offers insights into how tumors develop, progress, and potential targets for treatment. Tumor transcriptomics is crucial for personalized medicine as it allows for the identification of key mutations driving cancer and facilitates the customization of treatment plans based on the specific transcriptional profile of each tumor.
Tumor Transcriptomics Market- Market Dynamics
Increasing research and development in diagnostics and drug discovery to propel market demand
The growth of the transcriptomics market is being actively driven by increasing research and development in diagnostics and drug discovery, the rising prevalence of chronic diseases like cancer and neuromuscular disorders, and expanding applications of transcriptomics. Transcriptomics plays a crucial role in accelerating disease diagnostics, especially with the growing global burden of chronic diseases such as cancer and diabetes. For example, according to the GLOBOCAN 2020 report, there were approximately 19.2 million new cancer cases and 9.9 million cancer deaths worldwide. This increasing patient population is expected to positively impact market growth. The market growth is anticipated to be significantly driven by product launches, expansions, collaborations, and acquisitions from key market players. For example, in February 2020, Caris Life Sciences introduced its latest genomic profiling offering, MI Transcriptome, which utilizes Whole Transcriptome Sequencing (WTS). This technology enables detailed RNA profiling of patients' tumors, complementing Caris' comprehensive approach that assesses DNA, RNA, and proteins to tailor therapies accurately. Such launches are poised to positively impact market expansion. Similarly, in February 2020, Dovetail Genomics expanded its global reach with the availability of Dovetail HiChIP and Micro-C Kits, aiming to broaden its customer base worldwide and further stimulate market growth.
Tumor Transcriptomics Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.10% over the forecast period (2024-2032)
Based on Product type segmentation, instruments was predicted to show maximum market share in the year 2023
Based on technology segmentation, sequencing technologies was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
The Global Tumor Transcriptomics Market is segmented on the basis of Product type, Application, Technology, and Region.
The market is divided into three categories based on Product type: Consumables, Instruments, and Other Products. In terms of product types, instruments hold a dominant position due to their critical role in conducting transcriptomic analyses. Instruments such as microarray scanners, real-time quantitative PCR machines, and next-generation sequencing platforms are essential for generating data and performing high-throughput transcriptome analysis. These instruments are pivotal for researchers and clinicians seeking to understand disease mechanisms, identify biomarkers, and develop personalized treatment strategies, thereby solidifying their dominance in the market.
The market is divided into three categories based on technology: Microarray, Real-time Quantitative Polymerase Chain Reaction (Q-PCR) and Sequencing Technologies. In the transcriptomics market, sequencing technologies dominate the technology segment due to their advanced capabilities in analyzing the transcriptome with high resolution. RNA sequencing (RNA-Seq) has revolutionized transcriptomic studies by allowing researchers to detect rare transcripts, study alternative splicing events, and quantify gene expression levels accurately. This technology's ability to provide comprehensive insights into gene expression profiles and molecular pathways has made it indispensable in both research and clinical applications, driving its dominance in the market.
Tumor Transcriptomics Market- Geographical Insights
From a territorial perspective, this market covers a vast geographic area, stretching across North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Individual countries within these regions create further market classifications. North America is projected to lead the market, fueled by favorable government initiatives, rising healthcare spending, a robust presence of industry leaders, advanced healthcare infrastructure, heightened awareness among healthcare stakeholders about available technologies, and a high concentration of market players, particularly in the United States.
The Tumor Transcriptomics market refers to the sector focused on the study and analysis of gene expression patterns in tumors. It involves technologies and methodologies aimed at understanding the transcriptome of cancer cells, which can provide insights into tumor biology, disease progression, and potential therapeutic targets. Key strategies adopted by companies in this market include developing advanced sequencing technologies, establishing collaborations with research institutions and pharmaceutical companies for data sharing and clinical trials, and enhancing bioinformatics capabilities to interpret complex genomic data effectively. The market is driven by increasing research investments in oncology, personalized medicine approaches, and the growing demand for targeted cancer therapies based on genomic profiling. Various market participants in the transcriptomics sector continue to focus on innovating new instruments and techniques for disease diagnostics.
In August 2021, HTG Molecular Diagnostics, Inc. launched its HTG Transcriptome Panel in the U.S. and Europe. This panel, utilizing HTG EdgeSeq technology, can measure nearly 20,000 mRNA targets and has demonstrated repeatability for diagnosing multiple cancers. These advancements and launches are expected to bolster growth within this segment.
GLOBAL TUMOR TRANSCRIPTOMICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT
10x Genomics
Agilent Technologies Inc.
BGI Genomics
Bio-Rad Laboratories Inc.
Dovetail Genomics
F. Hoffmann-La Roche AG
Fluidigm Corporation
GE Healthcare
Illumina Inc.
Merck KGaA
Natera Inc.
Others